Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Stanley Muller on Jun 12th, 2026

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $76.1250.

A number of equities research analysts have recently commented on CRNX shares. Citizens Jmp reaffirmed a “market outperform” rating and issued a $95.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Thursday. Lifesci Capital upgraded Crinetics Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 13th. Oppenheimer lowered their price target on Crinetics Pharmaceuticals from $87.00 to $84.00 and set an “outperform” rating for the company in a report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. Finally, Wall Street Zen upgraded Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, May 17th.

View Our Latest Stock Report on Crinetics Pharmaceuticals

Insider Activity at Crinetics Pharmaceuticals

In other news, insider Stephen F. Betz sold 10,612 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $396,570.44. Following the completion of the sale, the insider directly owned 137,101 shares of the company’s stock, valued at $5,123,464.37. The trade was a 7.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jeff E. Knight sold 85,163 shares of the business’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $40.10, for a total transaction of $3,415,036.30. Following the sale, the insider directly owned 105,289 shares of the company’s stock, valued at $4,222,088.90. This represents a 44.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 127,667 shares of company stock worth $5,003,411. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its position in Crinetics Pharmaceuticals by 107.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock valued at $30,000 after acquiring an additional 331 shares during the period. Headlands Technologies LLC purchased a new stake in Crinetics Pharmaceuticals during the second quarter valued at about $30,000. Parallel Advisors LLC grew its position in Crinetics Pharmaceuticals by 34.6% during the fourth quarter. Parallel Advisors LLC now owns 1,225 shares of the company’s stock valued at $57,000 after acquiring an additional 315 shares during the period. Arax Advisory Partners grew its holdings in shares of Crinetics Pharmaceuticals by 131.2% during the 4th quarter. Arax Advisory Partners now owns 1,498 shares of the company’s stock worth $70,000 after purchasing an additional 850 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Crinetics Pharmaceuticals during the 2nd quarter worth about $45,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Crinetics Pharmaceuticals Stock Performance

CRNX stock opened at $33.53 on Friday. The stock has a market capitalization of $3.54 billion, a P/E ratio of -6.54 and a beta of 0.24. Crinetics Pharmaceuticals has a one year low of $25.83 and a one year high of $57.99. The company has a 50 day moving average price of $37.38 and a two-hundred day moving average price of $42.69.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.23) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.01). The firm had revenue of $10.73 million during the quarter, compared to analysts’ expectations of $8.51 million. Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The firm’s revenue was up 2873.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.04) earnings per share. Research analysts forecast that Crinetics Pharmaceuticals will post -4.85 earnings per share for the current fiscal year.

Crinetics Pharmaceuticals Company Profile

(Get Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.